About 3SBio
3SBio is a publicly listed company based in Shenyang (China) founded in 1993. Fully integrated Chinese Biopharm with a focus on nephrology, oncology, supportive cancer care, inflammation and infectious diseases. The company has 5,580 employees. 3SBio has completed 2 acquisitions, including Shanghai CP Guojian Pharmaceutical and Sirton Pharmaceuticals. Its website 3sbio.com draws about 17 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals.
Company details
3SBio develops, manufactures, markets, and sells biopharmaceuticals. Its products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; and EPIAO, an injectable recombinant human erythropoietin for anemia associated with chronic kidney disease (CKD) and chemotherapy, as well as to reduce allogeneic blood transfusion in surgery patients. The company also offers IV Iron Sucrose, an iron sucrose injection product for iron deficiency anemia; SEPO, an injectable product for anemia associated with CKD, as well as CIA; and Sparin, an injectable low-molecular-weight heparin calcium product for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. In addition, it provides Intefen, a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin 2 product for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; and Gan Xin, a metadoxine drug for alcoholic liver disease. Further, the company offers Qiming Keli for Type 2 diabetic retinopathy; Yi Li Xi, a TZDS antidiabetic drug; Man di, an OTC drug for baldness; Lai Zi, a tacrolimus ointment for atopic dermatitis; Di Su, a BCG-PSN injection for chronic bronchitis, cold, and asthma; Lai Duo Fei for allergic rhinitis and antihistamines; Liranaftate, a glucosinolates carbamate antifungal drug for the treatment of tinea pedis, tinea corporis, and tinea cruris; and Amikacin to treat trauma infection caused by bacteria, as well as distributes anti-cancer drugs, such as Docetaxel, Anastrozole, and Azasetron.
- Annual Revenue$2.47 B (USD)94.34as on Dec 31, 2025
- Net Profit$1.18 B (USD)305.9as on Dec 31, 2025
- EBITDA$1.55 B (USD)263.36as on Dec 31, 2025
- Employee Count5,580
- Investments & AcquisitionsShanghai CP Guojian Pharmaceutical
& 1 more
People of 3SBio
5 people are tracked at 3SBio (3 in leadership, 2 in team); the tracked headcount is 5,580.
| Name | Role | Group |
|---|---|---|
Xiang H. | Australia CEO | Leadership |
Jing Lou | Chairman, President & Chief Executive Officer | Leadership |
Hao Zhang | Head Of Corporate Development | Leadership |
Sunnie Huang | HRVP | Team |
Jane Rey Cui | Business Development Manager/strategic Investment | Team |
Complete people profiles for 3SBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of 3SBio
3SBio is a publicly listed company on the HKEX with ticker symbol 1530 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Feb 2007
- Listed onNASDAQ: SSRX
- Listed entity3SBio, Inc.
- Exchange sectorHealth technology
- ISINKYG8875G1029
- Share price14.44 HKD (-2.17% on the day) · 2026-10-14
- Market capitalisation37,465,619,204.00 HKD
- Price to earnings4.0
- EPS (diluted, trailing year)3.65 HKD
- Dividend yield1.69%
- Volume (last session)23,201,336
Financials of 3SBio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 19.19B HKD | 9.20B HKD | 12.04B HKD |
| 2024 | 9.88B HKD | 2.27B HKD | 3.31B HKD |
| 2023 | 8.64B HKD | 1.71B HKD | 3.02B HKD |
| 2022 | 7.98B HKD | 2.23B HKD | 2.72B HKD |
| 2021 | 7.69B HKD | 1.99B HKD | 2.48B HKD |
Detailed financial statements for 3SBio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 3SBio
3SBio has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Shanghai CP Guojian Pharmaceutical and Sirton Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody drugs for cancer and immune diseases are developed. | cpgj-pharm.com | Shanghai, China | 2002 | Nov 2015 | $214M | |
Injectable pharmaceutical products are manufactured under contract. | sirton.it | Villa Guardia, Italy | 1944 | Jan 2015 | •••• |
Complete acquisition details for 3SBio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of 3SBio
4 dated milestones of 3SBio across 22 years, from founding to its latest funding, stage changes and deals.
- Founded 3SBio is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Sirton Pharmaceuticals.
- Acquisition Acquires Shanghai CP Guojian Pharmaceutical.
Web traffic of 3SBio
The website of 3SBio (3sbio.com) receives about 17.5K visits a month.
- Monthly visits17.5K
▲ 42.6% vs previous month
Websites whose visitors overlap most with 3SBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hansoh.cn | 100% | #3,059,724 | View details | ||
bms.com.cn | bms.com.cn | 100% | – | ||
| astrazeneca.com.cn | 100% | #6,860,486 | View details | ||
| yangzijiang.com | 100% | #559,311 | View details | ||
| novartis.com | 100% | 948.8K | #58,822 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for 3SBio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about 3Sbio
Complete news archive for 3SBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 3SBio
3SBio was founded in 1993.
3SBio is headquartered in Shenyang, China. It is registered at Shenyang, Liaoning, China.
3SBio has 5,580 employees.
Annual revenue of 3SBio is $2.47B as on Dec 31, 2025.
3SBio develops, manufactures, markets, and sells biopharmaceuticals. Its products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; and EPIAO, an injectable recombinant human erythropoietin for anemia associated with chronic kidney disease (CKD) and chemotherapy, as well as to reduce allogeneic blood transfusion in surgery patients. The company also offers IV Iron Sucrose, an iron sucrose injection product for iron deficiency anemia; SEPO, an injectable product for anemia associated with CKD, as well as CIA; and Sparin, an injectable low-molecular-weight heparin calcium product for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. In addition, it provides Intefen, a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin 2 product for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; and Gan Xin, a metadoxine drug for alcoholic liver disease. Further, the company offers Qiming Keli for Type 2 diabetic retinopathy; Yi Li Xi, a TZDS antidiabetic drug; Man di, an OTC drug for baldness; Lai Zi, a tacrolimus ointment for atopic dermatitis; Di Su, a BCG-PSN injection for chronic bronchitis, cold, and asthma; Lai Duo Fei for allergic rhinitis and antihistamines; Liranaftate, a glucosinolates carbamate antifungal drug for the treatment of tinea pedis, tinea corporis, and tinea cruris; and Amikacin to treat trauma infection caused by bacteria, as well as distributes anti-cancer drugs, such as Docetaxel, Anastrozole, and Azasetron.
Yes, 3SBio is publicly traded on HKEX under the ticker symbol 1530.
3SBio has made 2 acquisitions, including Shanghai CP Guojian Pharmaceutical, and Sirton Pharmaceuticals.